bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive tests for early-stage cancer detection, will join Federal Supply System (FSS) officials today in a joint presentation. The event will highlight the Veterans Health Administration (VHA) award that has added CyPath® Lung to the FSS procurement system, making it available for the VA’s 1,380 healthcare facilities. The presentation will take place at a meeting of the National Association of Veterans’ Research and Education Foundations (NAVREF).
The Veterans Health Administration (VHA), part of the U.S. Department of Veterans Affairs (VA), serves 9.1 million veterans annually and is the largest integrated healthcare system in the country. Through the Federal Supply Schedule (FSS), which is used by both the VHA and the Military Health System, CyPath® Lung is now available to healthcare providers, streamlining access to advanced healthcare products and services.
Maria Zannes, President and CEO of bioAffinity Technologies, commented, “Being able to offer CyPath® Lung to VA healthcare facilities, which include over 170 medical centers and more than 1,000 outpatient sites nationwide, presents a significant opportunity. We are grateful that NAVREF recognized the importance of sharing information about CyPath® Lung with our VA colleagues, helping industry partners—including large pharma, biotech firms, and medical professionals—learn about the invaluable support we received from the VA’s National Acquisition Center professional staff.”
Rashi Romanoff, CEO of NAVREF, said, “NAVREF is proud to support collaborations like the one between bioAffinity Technologies and the Veterans Health Administration. The inclusion of CyPath® Lung in the Federal Supply Schedule highlights the power of public-private partnerships to bring innovative diagnostic tools to the VA, ultimately improving health outcomes for veterans. We commend both bioAffinity and the VA for their dedication to advancing lung cancer detection and care.”
NAVREF is a nonprofit organization dedicated to advancing the research and education efforts of VA-affiliated nonprofits across the VA system. By providing resources, advocacy, and expertise, NAVREF helps its members enhance veterans’ lives through innovative research and educational initiatives. NAVREF has also worked with the VA to streamline clinical trial opportunities for veterans, improve care, and enhance education for VA healthcare staff, veterans, and their families. As a member of NAVREF’s Industry Partner Consortium, bioAffinity Technologies is committed to supporting these efforts.
Veterans face a higher risk of lung cancer due to factors such as older age, smoking, and environmental exposure during and after military service. The VA’s Lung Precision Oncology Program (LPOP) encourages annual lung cancer screenings for high-risk individuals. CyPath® Lung is particularly useful for patients with positive screening results, especially when a low-dose computed tomography (LDCT) scan reveals indeterminate pulmonary nodules. It provides a noninvasive alternative to a “wait and see” approach or an unnecessary invasive procedure, such as a biopsy.
About CyPath® Lung
CyPath® Lung utilizes advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis determines whether cancer is present or if the patient is cancer-free. The test incorporates a fluorescent porphyrin, meso-tetra (4-carboxyphenyl) porphyrin (TCPP), which is preferentially absorbed by cancer and cancer-related cells. Clinical studies have shown that CyPath® Lung has 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in high-risk patients with small lung nodules less than 20 millimeters. Early detection and treatment of lung cancer can significantly improve outcomes and increase patient survival.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (Nasdaq: BIAF) focuses on noninvasive early-stage cancer diagnosis, lung diseases, and broad-spectrum cancer treatments. The company’s flagship product, CyPath® Lung, is a noninvasive test that has demonstrated high sensitivity, specificity, and accuracy in detecting early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies.